NEW YORK (360Dx) – Novacyt said today that its Lab21 Products protein diagnostics division has entered an agreement to acquire Omega Diagnostics' infectious disease business for up to £2.2 million ($2.9 million).

The acquisition fee consists of £1.8 million upon completion, £175,000 paid after 12 months and upon completion of technology transfer, and £200,000 paid upon the successful accreditation to certain standards of an Omega Diagnostics production facility in Axminster, UK.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.